Fig. 2
PK profile and antitumor effects of BD0801 in the PC9 lung cancer mouse models. (A) BD0801 has the same affinity for the rat, mouse, and human VEGF over the same concentration range. (B) PC9 cells were implanted subcutaneously into the right flank of Balb/c nude mice. When the average tumor volume reached ~ 150 mm3, the mice received a single intravenous injection of different concentrations of BD0801. Blood levels of BD0801 were analyzed by ELISA, n = 3/group. (C) Tumor volume of PC9 tumor-bearing Balb/c nude mice was administrated with the vehicle, AZD9291, or BD0801 biweekly (n = 6/group). (D) Bodyweight of PC9 tumor-bearing Balb/c nude mice was administrated with the vehicle, AZD9291, or BD0801 biweekly (n = 6/group). The error bars represent SEM. IV, intravenous; PO, oral gavage; BIW, biweekly. P-value was calculated based on the tumor volume comparing to the vehicle group using two-way ANOVA; **, P < 0.01. The tumor images are included in Supplementary Fig. S5